Cleerly a New York-based company creating a new standard of care for heart disease, announced that it has closed a Series C financing round of $192 million. This new funding brings the total raised by the fast-growing health care company to $248 million, which includes its Series B round in 2021.
The oversubscribed funding round was led by funds and accounts advised by T. Rowe Price Associates, Inc. and T. Rowe Price Investment Management, Inc., and Fidelity Management and Research Company. They are joined by additional investors spanning the health care, pharmaceutical, and technology sectors, including Sands Capital, Piper Sandler’s Merchant Banking and Heartland Healthcare Capital funds, Mirae Asset Capital, Peter Thiel, Breyer Capital, and Novartis. Cleerly’s existing investors also participated in the financing and include Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures, and DigiTx Partners.
This funding round will enable Cleerly to expand its team as well as extend its commercial reach to broaden patient and physician access to its comprehensive technology-enabled care pathway across the entire continuum of disease presentation—from early diagnosis of heart disease to ensuring that ongoing treatments are effective for those who have that elevated risk or symptoms.
Company: Cleerly, Inc.
Round: Series C
Funding Month: July 2022
Lead Investors: T. Rowe Price Associates, Inc., T. Rowe Price Investment Management, Inc., and Fidelity Management and Research Company
Additional Investors: Sands Capital, Piper Sandler’s Merchant Banking and Heartland Healthcare Capital funds, Mirae Asset Capital, Peter Thiel, Breyer Capital, and Novartis. Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures, and DigiTx Partners.
Company Website: http://crunchbase.com/
Software Category: AI-Driven Digital Care platform
About the Company: d by James Min, MD, FACC, FESC, MSCCT, CEO and founder, Cleerly leverages FDA-cleared, value-based diagnostic solutions driven by machine intelligence to enable comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Its AI-enabled approach to evaluating coronary computed tomography (CT) angiograms allows physicians to easily identify, characterize and qualify atherosclerosis (plaque) build-up in the walls of the heart arteries. This information promotes an accurate understanding of a patient’s risk of heart attack and represents a marked shift from the way that heart disease has been historically assessed using indirect surrogate markers of disease.